Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation

June 2019
Oncology Practice Management;Jun2019, Vol. 9 Issue 6, p40
Academic Journal
No abstract available.


Related Articles

  • Bevacizumab/mitomycin: Atypical haemolytic uraemic syndrome, treated with eculizumab: case report.  // Reactions Weekly;Jun2019, Vol. 1756 Issue 1, p78 

    A 71-year-old woman developed pruritus and acneiform skin rash during treatment with erlotinib for lung adenocarcinoma. Additionally, the acneiform skin rash and pruritus worsened following concomitant administration of erlotinib and aprepitant for lung adenocarcinoma.

  • High insulin levels linked with worse prognosis in breast cancer patients.  // Women's Nutrition Connection;Jan2016, Vol. 19 Issue 1, p3 

    The article reports that according to a study, women having metastatic breast cancer and more than normal insulin level have significantly worse prognosis and mentions that healthy diet, exercise, and drug like metformin is good for prevention of diabetes and lower insulin level.

  • Trastuzumab emtansine saves costs in HER2+ mBC.  // PharmacoEconomics & Outcomes News;Feb2016, Vol. 745 Issue 1, p34 

    The article focuses on a study published in by biotechnology company Genentech at the 38th Annual San Antonio Breast Cancer Symposium held in the U.S., which shows that treatment of HER2-positive metastatic breast cancer (mBC) with trastuzumab emtansine is cost effective.

  • Antrasiklin ve taksan rezistant metastatik meme kanseri tedavisinde eribulin mesilat etkinlik ve tolerabilitesi. Tek merkez deneyimi. Geredeli, Çağlayan // Ortadogu Medical Journal / Ortadogu Tip Dergisi;2019, Vol. 11 Issue 1, p10 

    Aim: The microtubule inhibitor eribulin mesylate anthracycline and taxane resistance have been accepted for use in patients with metastatic breast cancer. The goal is to investigate the efficacy of eribulin mesylate. Material and Methods: Retrospective study was carried out in Istanbul...

  • Paclitaxel.  // Reactions Weekly;2/13/2016, Vol. 1588 Issue 1, p210 

    A case study is presented for 53 year old woman having treatment with paclitaxel for metastatic breast cancer developed hair loss, impaired hair growth and changes to her nails due to this treatment impact.

  • Rare breast and subcutaneous metastases from pancreatic neuroendocrine tumor: a case report. Bosco, Dorotea; Perrotti, Salvatore; Spatola, Corrado; Vecchio, Giada Maria; Latino, Rosalia; Di Cataldo, Antonio // World Journal of Surgical Oncology;7/11/2019, Vol. 17 Issue 1, pN.PAG 

    Background: Neuroendocrine tumors are a group of rare neoplasms, and the pancreatic neuroendocrine tumors (PNETs) represent only 1–2% of all pancreatic malignant tumors. The most common sites of these tumors include the gastrointestinal tract, lung, adrenal gland, and thyroid gland....

  • Albumin Biomimetic Nanocorona Improves Tumor Targeting and Penetration for Synergistic Therapy of Metastatic Breast Cancer. Cao, Haiqiang; Zou, Lili; He, Bin; Zeng, Lijuan; Huang, Yongzhuo; Yu, Haijun; Zhang, Pengcheng; Yin, Qi; Zhang, Zhiwen; Li, Yaping // Advanced Functional Materials;3/17/2017, Vol. 27 Issue 11, pn/a 

    The synergistic combination of photothermal and RNA interference therapy demonstrates great potential for effective treatment of metastatic breast cancer, but their efficacy is limited by the poor delivery efficiency to tumor. Herein, it is reported that an albumin biomimetic nanocorona...

  • Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. Ballinger, Tarah J.; Meier, Jason B.; Jansen, Valerie M. // Frontiers in Oncology;8/10/2018, pN.PAG 

    The majority of deaths from MBC are in patients with hormone receptor (HR) positive, HER2 negative disease. Endocrine therapy (ET) remains the backbone of treatment in these cases, improving survival and quality of life. However, treatment can lose effectiveness due to primary or acquired...

  • Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study). Kei Kimizuka; Kenichi Inoue; Shigenori E. Nagai; Tsuyoshi Saito; Satoko Nakano; Kazushige Futsuhara; Hirofumi Yamada; Shiori Kaneko; Takashi Sakurai; Satoshi Hata; Masafumi Kurosumi // Journal of Nippon Medical School;Jun2019, Vol. 86 Issue 3, p165 

    Background: Fulvestrant 500 mg has been an option for endocrine therapy for advanced or recurrent breast cancer after prior endocrine treatment since November 2011 in Japan. This study aimed to clarify the effectiveness and safety of fulvestrant 500 mg in clinical settings. Methods: This was a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics